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Background: There is limited information regarding the safety, feasibility and acceptability of behaviour-
change interventions to increase physical activity (PA) and reduce sedentary behaviour among people 
with MS. Prior to evaluating efficacy, it is important to identify problems with feasibility and 
acceptability, which may undermine effectiveness.  
Objective: To examine the safety, feasibility and acceptability of a behaviour-change intervention to 
increase PA and reduce sedentary behaviour among people with MS. 
Methods: Sixty people received a three-month intervention or usual care. Fatigue, pain and adverse 
events (AEs) were assessed. Feasibility and acceptability were explored through focus groups with 
physiotherapists and interviews with participants. Fidelity to intervention content, delivery skills, 
programme receipt and programme task were assessed.  
Results: There was no difference in AE event rate between groups (p=0.965). Fatigue and pain were not 
higher in the intervention group at 3 or 9 months. Therapists reported the intervention was feasible to 
deliver and fidelity was acceptable. Twenty-nine participants (97%) attended at least 75% of sessions. 
Participants found the intervention acceptable but suggested some amendments were required to 
intervention components.   
Conclusion: The intervention was safe, feasible and acceptable. Although modifications are required to 
intervention components, the intervention warrants further evaluation in a future trial. 
Trial registration: Changing physical activity behaviour in people with MS: the iStep-MS trial; 
https://doi.org/10.1186/ISRCTN15343862; ISRCTN15343862
Introduction 
Physical activity (PA) and reduced sedentary behaviour are associated with milder disability, better 
mental health and less fatigue among people with multiple sclerosis (MS).1-3 However, people with MS 
are insufficiently active and spend prolonged time in sedentary behaviour.4,5 Behaviour-change 
interventions are a potential method for increasing PA and reducing sedentary behaviour in people with 
MS.  
 
A recent meta-analysis concluded that behaviour-change interventions for people with MS improved 
self-reported PA.6 However, as self-reported PA is only weakly correlated with objectively measured PA 
in people with and without MS,7-9 it is recommended that objective measures of PA and sedentary 
behaviour are used to determine the effectiveness of behaviour-change interventions.6,8 Of four studies 
that assessed effects on objectively measured PA,6 only one found a between-group difference in favour 
of the intervention immediately post-intervention but not at 6 months post-intervention.1 One study has 
examined the effect of a behaviour-change intervention on self-reported sitting time in people with MS 
with positive results.10 However, as PA and sedentary behaviour are distinct concepts, and guidelines 
recommend both increasing PA and reducing sedentary behaviour for health benefits,11 interventions 
targeting both PA and sedentary behaviour are required. 
 
Prior to evaluating efficacy of such interventions, it is important to identify problems with feasibility, 
acceptability and fidelity to the intervention, which may undermine effectiveness. This is an important 
step in evaluating a complex intervention that can enable differentiation between true ineffectiveness 
and implementation failure,12 and has not been well described in this context to date. Of the 14 studies 
included in the meta-analysis of behaviour change interventions,6 one reported fidelity to content13 and 
another reported fidelity to delivery.14 No study explored the feasibility of delivering behaviour-change 
interventions to change PA behaviour from the perspective of the intervention provider. Only two 
studies asked participants for feedback on the intervention, both using a questionnaire with open-ended 
questions.15,16 Additionally, the safety of behaviour-change interventions to change PA behaviour is 
unclear. Seven of the 14 studies did not mention adverse events (AEs),14,17-19 five stated no AEs were 
recorded without providing information on how this was assessed,1,16,20 one assessed AEs in the 
intervention group only,15 and one reported related-AEs only.13  
 
We therefore aimed to examine the safety, feasibility, acceptability and effects of a behaviour-change 
intervention to increase PA and reduce sedentary behaviour among people with MS, and to explore the 
feasibility of conducting a larger trial to evaluate effectiveness. 
 
Materials and Methods 
We conducted a randomised controlled trial with parallel process evaluation comparing a physiotherapist-
led behaviour-change intervention to usual care. Participants were recruited from an MS Therapy Centre 
in England, and the MS Society UK website from April-September 2017. Inclusion criteria were a self-
reported diagnosis of MS, ability to independently walk within the home with or without a walking aid, 
relapse-free for the past 3 months, and free of unstable medical conditions such as unstable angina that 
would make it unsafe to participate in PA. Participants had to be able to travel to the centre, converse in 
English and have sufficient cognition to complete assessments and participate in the intervention. 
Exclusion criteria were pregnancy and ongoing participation in other trials. Assessments were conducted 
at baseline, 3 and 9 months. Further details on the recruitment and assessment are described in the 
protocol.21 Approval was obtained from Brunel University London’s Research Ethics Committee. 
Participants gave informed written consent prior to completing the baseline assessment.   
 
Following baseline assessments, participants were randomly allocated to the intervention or usual care 
control group in a 1:1 ratio. Allocation was performed by an individual independent to the study 
according to a computer-generated random schedule in random permuted blocks of 2 or 4. The 
allocation sequence was placed in sequentially numbered, opaque, sealed envelopes. Following each 
baseline assessment, an envelope was drawn sequentially by a researcher who informed the participant 
of their group allocation. 
 
Participants and therapists were not blind to group allocation. Although assessors were also not blind, 
self-reported questionnaires were used and participants received standardised instructions to minimise 
detection bias. Assessment of objective PA and sedentary behaviour is unlikely to be influenced by the 
assessor being aware of group allocation. Data were processed and analysed by a researcher blind to 
group allocation.  
 
Intervention 
Participants in the intervention group received four face-to-face sessions, each lasting 30-45 min, with a 
physiotherapist at the centre over three months, supported by a handbook and Yamax SW-200 
digiwalker pedometer.22 The intervention, which was delivered by four therapists, is described in the 
protocol21 and supplemental material. Briefly, physiotherapists discussed increasing PA and step-count 
and reducing sedentary behaviour with participants using behaviour-change techniques,23 guided by the 
handbook. The handbook contained pre-reading and reflection to be completed by the participant prior 
to each session. Therapists received a specific handbook with additional comments. Participants set and 
recorded PA, sedentary behaviour, and step-count goals in sessions 1-3, and monitored and recorded 
these behaviours between sessions using diaries included in the handbook (examples provided in 
supplemental material). Therapists received three half-day training sessions led by a behaviour-change 
technique trainer; two prior to delivering the intervention and one feedback session after they had each 
completed at least one intervention session. We video-recorded an example of the trainer delivering a 
session to a person with MS on our advisory group and used this to support training. The trainer 
reviewed audio-recordings of one session for each therapist, and provided feedback on this in the third 
training session. Brief cognitive-behavioural strategies, which were targeted at addressing perceived 
stress and coping with negative emotions in relation to adjusting to MS,24 were included in both the 
training and handbook.  
 
Procedures 
Data on sociodemographic characteristics, MS-specific characteristics, anthropometric measures, and the 
MS Impact Scale were collected at baseline. 
 
Safety was determined by assessing pain, using the pain item on the EQ-5D-5L, and fatigue, using the 
Modified Fatigue Impact Scale (MFIS), at each assessment. The EQ-5D-5L asks people to identify the best 
description of their pain on a five point scale, from no pain or discomfort to extreme pain or discomfort. 
The EQ-5D-5L is linearly related to EDSS score in people with mild-to-moderate disability.25 Specifically, 
the pain item on the EQ-5D-5L demonstrates excellent discriminatory capacity and no ceiling effect 
among people with MS.25 At 3 and 9 months, participants were asked if they had experienced a fall, 
relapse or other AE, the number of events experienced, and a description of the event, using 
standardised questioning.   
 
MVPA and step-count were measured with the Actigraph GT3X accelerometer. Non-wear-time was 
defined as ≥90 consecutive minutes of 0 counts26 and validated against participants’ wear-time diaries. 
Participants with at least 3 days of 10 hours wear-time were included in analysis.27 MVPA was indicated 
by a cut-point of ≥1745 counts/minute.28 Sedentary (sitting and lying), standing and stepping time, 
respectively, were measured using the activPAL3µ activity monitor, which was worn on the person’s thigh 
for 7 days. Identification of non-wear time is described in supplemental material. Participants had at least 
2 days of 10 hours of wear-time. 
 
Self-reported time in moderate, vigorous, and walking activity were assessed using the International 
Physical Activity Questionnaire short-form. Walking capability was assessed using the Twelve Item MS 
Walking Scale (MSWS-12); higher scores indicated poorer walking capability. Fatigue was assessed using 
the MFIS; higher scores indicated greater impact of fatigue on a person’s activities. Self-efficacy was 
assessed using the Multiple Sclerosis Self-Efficacy Scale (MSSE); higher scores indicated higher self-
efficacy. Participation over four domains (autonomy indoors, family role, autonomy outdoors, social life 
and relationships) was assessed using the Impact on Participation and Autonomy Questionnaire (IPA); 
higher scores represented poorer participation. Data on health service use over 9 months was obtained 
using a modified version of the Client Service Receipt Inventory (CSRI). Information on psychometric 
properties of measures is provided in the protocol.21  
 
Feasibility of training therapists and therapists’ experience of delivering the intervention was assessed 
by recording attendance at training sessions and via a focus group. Informed consent was obtained from 
therapists prior to conducting the focus group. A random selection of each therapists’ sessions were 
audio-recorded. Fidelity to intervention content and delivery skills was assessed by one person using a 
standardized tool.21 Percentage of expected content delivered was assessed; ≥70% was deemed 
acceptable.21 Therapists’ use of seven key skills, including empathic listening, partnership working and 
use of open-ended questions was rated as competent or not.  
 
Fidelity to programme receipt and programme task, respectively, were evaluated though attendance at 
sessions and percentage of sections completed in the handbook, including diaries. Semi-structured 
interviews were conducted with 15 and 10 participants from the intervention and control groups, 
respectively, to explore acceptability of the intervention and feasibility of a definitive trial.  
 
Data analysis 
Primary analyses were intention-to-treat. Secondary “per-protocol” analyses were conducted using data 
from participants who attended ≥75% of intervention sessions and completed follow-up to 9 months. 
Analyses were conducted using Stata (version 15.0). To examine the effect and safety of the intervention 
mean scores were compared between groups, at 3 and 9 months respectively, using ANCOVA adjusting 
for baseline score, and gender and type of MS as groups were unbalanced on these baseline 
characteristics. Logistic regression was used to compare the number of people with an AE at 9 months 
between groups. A negative binomial model, which accounts for overdispersion in the outcome, was 
used to compare the incidence of AEs over 9 months between groups. The focus group and interviews 
were analysed through Framework Analysis.29  
 
Results 
Sixty people were randomly allocated to receive the intervention or usual care (figure 1). The groups 
were mostly similar on baseline characteristics (table 1). There were more women and more people 
with relapsing remitting MS in the control group. More people in the intervention group had secondary 
progressive MS. Outcomes at baseline are described in table 2. Twenty-nine participants (97%) attended 
at least 75% of sessions. Fifty-five (92%) and fifty-two people (87%) attended the 3 and 9 month 
assessments. Health service use in both groups over 9 months is described in supplemental material. 
Activity data were obtained from between 84% and 93% of participants (table 2 and 3). Wear-time for 
activity monitors is presented in supplemental material.  
 
Safety 
Fatigue was lower in the intervention group at 3 (mean difference [MD]: -6.19, 95% CI -12.06 to -0.31) 
and 9 months (MD: -8.97, 95% CI -16.21 to -1.72; table 4). There was no difference in pain between 
groups at 3 months (MD: -0.20, 95% CI -0.56 to 0.17). Pain was lower in the intervention group at 9 
months (MD: -0.53, 95% CI -0.96 to -0.10). Twenty-two participants in each group experienced at least 
one AE (table 5). There was no difference between groups in the proportion of people who experienced 
an AE (odds ratio 0.83, 95% CI 0.22 to 3.14, p=0.788) or the incidence of an AE (rate ratio 0.98, 95% CI 
0.47 to 2.07, p=0.965). Two participants in the intervention group experienced unrelated serious AEs; 
one person was admitted to hospital for a planned procedure and another person was admitted to 
hospital with pleurisy.  
 
Feasibility and acceptability 
Training was deemed adequate in relation to content and approach. The therapists’ handbook, use of a 
videoed example of delivering a session, and feedback on their delivery of the first face-to-face session 
were particularly valued. Therapists reported that the programme was feasible to deliver within their 
current workload, although flexibility around timing of sessions and time for familiarisation was 
required. This required a commitment to invest ‘out of study’ time to consolidate their own learning and 
peer-support to clarify aspects between and after sessions, which improved their confidence to deliver 
the intervention.  
 
Fidelity to content delivery was ≥70% for all sessions (range 89% to 98%). All therapists were rated as 
competent across key delivery skills. Median completion of the handbook was 86.7% (range 23.3% to 
100%); 75% of participants completed ≥70% of the handbook. While overall, the handbook was both 
well received and deemed useful, some participants suggested improvements to the usability of the 
handbook. These included an online version, a reduction in some of the pre-session content and clearer 
signposting between sections. Indicative quotes representing its acceptability and these suggestions are 
provided in supplemental material. 
 
Participants with MS found the length of intervention, and frequency and length of sessions acceptable. 
Intervention structure and therapist continuity facilitated the development of a supportive participant-
therapist relationship, which fostered a sense of relatedness and autonomy that was crucial to enhance 
self-efficacy for PA engagement. Self-management strategies such as pacing, goal-setting, setting 
graded tasks, self-monitoring and action-planning were well received. More detail on participants’ 
experiences of the intervention is presented elsewhere.30  
 
The pedometer provided visual, objective feedback, which enhanced participants’ awareness of and 
motivation to increase PA. However, eight participants reported issues with attachment and accuracy of 
the pedometer, two expressed a desire for a monitor that could measure MVPA in addition to step-
count, six purchased an alternative monitor, and two used their phone to measure step-count.   
 
Feasibility of definitive trial 
Communication with the research team was acceptable to participants. Study information was deemed 
adequate and understanding among participants about the randomisation process was good. 
Participants found the assessment process acceptable. In general, activity monitoring was well-
tolerated. Specific issues with the Actigraph included forgetting to attach it (n=6), discomfort caused by 
the waistband or from the monitor shifting position (n=5), and difficulty removing the monitor in 
relation to bladder urgency (n=3). Skin irritation from wearing the activPAL3µ, visibility of the 
activPAL3µ under clothing, and the intrusiveness of wearing the monitor at night were each mentioned 
by one participant respectively.  
 
Effects 
Results from intention-to-treat analysis are presented in tables 3 and 4. There was no difference in 
sedentary time, step-count, MVPA, or self-reported walking or MVPA between groups. Stepping time 
differed between groups at 3 (MD: 0.17hr, 95% CI 0.04 to 0.31) and 9 months (MD: 0.27hr, 95% CI 0.06 
to 0.48), in favour of the intervention group. In addition to improvements in fatigue and pain (table 4), 
there were between-group difference in scores for MSWS-12 (MD: -7.11, 95% CI -14.04 to -0.19) at 3 
months, and MSSE (MD: 9.10, 95% CI 0.39 to 17.81), autonomy indoors (MD: -0.36, 95% CI -0.69 to -
0.04) and autonomy outdoors (MD: -0.46, 95% CI -0.90 to -0.02) at 9 months, in favour of the 
intervention group. Results from per-protocol analyses were nearly identical (supplemental material).   
 
Discussion  
Findings show that a physiotherapist-led behaviour-change intervention of four face-to-face sessions 
supported by a handbook and pedometer was safe, feasible and acceptable to people with MS. The 
following criteria were proposed a priori to determine if the intervention warrants further evaluation in 
a larger trial21: no evidence of a greater number of AEs or greater negative change in pain and fatigue in 
the intervention group in comparison to the control group; no indication of a dominant negative theme 
from interviews with participants and physiotherapists; attrition rate <20%. We found no evidence that 
the rate of AEs differed between groups or that pain or fatigue was higher in the intervention group at 3 
or 9 months. Although the proportion of participants who experienced an AE was relatively high in both 
groups, this may be because we systematically assessed AEs, regardless of their relatedness. Reporting 
of AEs in studies of behaviour-change interventions for people with MS has been poor to date with 
many not reporting information on AEs or not describing how AEs were assessed.  
 
Focus groups with therapists and interviews with participants indicated that the intervention was 
feasible to deliver and acceptable to receive. However, therapists committed additional time to 
consolidating their learning outside of formal training sessions and this likely contributed to the 
successful implementation of the intervention. Further, therapists used peer-support to clarify aspects 
between and after sessions, and consequently build their confidence. Therapists working in isolation 
may find it more difficult to deliver the intervention.  
 
Some amendments to intervention components are recommended prior to further evaluation. Some 
participants documented aspects covered in the handbook, specifically monitoring, in self-designed 
electronic spreadsheets. These were not included in the assessment of fidelity suggesting we 
underestimated handbook completion. The choice to document elsewhere as well as some people’s 
requests for an online version of the handbook, suggests an online version is required. However, there 
was no consensus regarding the “best” format, and alternative formats may be required depending on 
participant choice. While some participants suggested reducing pre-session content, the level of 
information required may depend on the individual. Clearer signposting between sections may improve 
the usability of the handbook without the need to reduce content. Although the pedometer was 
previously validated among adults with MS, several participants reported difficulties using it and doubts 
regarding its accuracy. As no study has examined the acceptability of behaviour-change interventions 
that incorporate an activity monitor for people with MS, it is unclear if these issues are specific to our 
sample or apply to the MS population more broadly. Additionally, the ability to monitor MVPA may 
contribute to greater changes in MVPA. However, the cost and accuracy of such a monitor needs to be 
considered against potential benefits.  
 
Although the intervention was less intensive than other behaviour-change interventions in the 
literature,31 it was delivered face-to-face, on a one-to-one basis, unlike previous interventions that 
delivered group sessions,32,33 or delivered telephone20,34 or internet interventions.17-19 Participants 
emphasised the strong therapeutic relationship was key to developing confidence and competence for 
PA enactment. Therefore, the potential challenges of delivering face-to-face sessions should be 
balanced against the benefits of a relatively low-resource intervention. 
 
Attrition was low at 3 and 9 months and missing data were minimal. Although a small number of 
participants reported issues with wearing the monitors such as forgetting to attach them or discomfort, 
monitoring was generally well-tolerated. The proportion of missing data was higher for activity 
monitors compared to other outcome measures, but not higher than levels of missing data reported in 
similar trials involving activity monitoring.35 Given we found objective measurement of PA and 
sedentary behaviour to be acceptable, and that it is recommended over self-report,8 we believe that 
accelerometers should be used in future trials examining effectiveness of behaviour-change 
interventions on PA and sedentary behaviour. However, the potential for up to 15% missing data should 
be considered when determining sample size.  
 
We found no evidence of between-group differences in step-count, MVPA or sedentary behaviour at 3 
or 9 months. However, our analysis was likely underpowered. Based on the standard deviation of 2,400 
steps/day observed in our sample at baseline, we estimate a sample of 382 individuals is required to 
detect a between-group difference of 800 steps/day at 3 months with 90% power and 5% significance. 
Only one study has found a positive effect on objectively measured PA among people with MS. Carter 
observed a between-group difference of 688.5 steps/day in favour of the intervention following a 3-
month intervention, but no difference at 9 months.1 We observed a positive treatment effect on fatigue 
at 3 and 9 months. In contrast, a meta-analysis of behaviour-change interventions reported no effect on 
fatigue,31 despite many of the interventions specifically targeting fatigue management.36-39 We also 
found between-group differences in self-efficacy, walking capability and participation at 9 months. 
Although a measure of PA self-efficacy may be more sensitive to change following the intervention, the 
MSSE includes a number of items such as confidence in ability to mobilise, complete activities of daily 
living, and manage symptoms of MS, which we believe are important to evaluate when determining the 
effects of a behaviour-change intervention. 
 
There are limitations to this study. We used the pain item on the EQ-5D-5L to assess bodily pain as we 
were unable to identify an instrument that specifically measured bodily pain in people with MS. 
Although the pain item on the EQ-5D-5L demonstrates excellent discriminatory capacity among people 
with MS,25 it may provide only a crude indication of pain and does not provide information about pain 
frequency. Although we attempted to be as inclusive as possible by not indicating a specific distance 
that individuals should be able to walk for, findings are not generalisable to non-ambulatory individuals. 
Similarly, participants were largely recruited from a single MS Therapy Centre and thus may not be 
representative of the wider population of adults with MS in England. The effect of the intervention on 
an objective measure of function such as a timed walk test was not assessed because we were unable to 
conduct such a test in participants’ homes. Analysis of efficacy was preliminary and should be 
interpreted with caution. The analysis lacked statistical power and the lack of an active comparator and 
blinding of participants potentially inflated the observed treatment effect. While there is currently no 
evidence as to what constitutes best practice to increase PA and reduce sedentary behaviour among 
people with MS, some form of active comparator should be included in a trial of clinical-effectiveness in 
order to control for the effect of attention and placebo on outcomes.   
 
In summary, our results show that a behaviour-change intervention to increase PA and reduce sedentary 
behaviour in people with MS was safe, feasible, acceptable, and showed some positive effects. 
Comparison of findings against pre-determined criteria indicates that the intervention warrants further 
evaluation to determine effectiveness on PA and sedentary behaviour.  
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Figure 1. Participant flow diagram 
